创造向未来:湿性AMD治疗进展及展望  

Treatment of wet age-related macular degeneration:Now and future

作　　者：丁小燕[1] 王志容 孙立梅[1] Ding Xiaoyan;Wang Zhirong;Sun Limei(Zhongshan Ophthalmic Centere,State Key Laboratory of Ophthalmology,Sun Yat-sen University,Guangzhou 510060,China)

机构地区：[1]中山大学中山眼科中心,眼科学国家重点实验室,广州510060

出　　处：《中华实验眼科杂志》2019年第1期63-68,共6页Chinese Journal Of Experimental Ophthalmology

基　　金：国家科学自然基金项目(81470645);广州市科技计划科技攻关、生物医药专项(201803010031);广东省科技计划项目(2016A020215096).

摘　　要：年龄相关性黄斑变性(AMD)是一种中心视力进行性、不可逆性丧失的疾病,是全球60岁以上老年人致盲的主要原因。目前抗VEGF是该病一线治疗方法,但存在注射频率高、全身不良反应大、对药物应答延迟甚至不应答及耐药性产生等问题。为解决这些问题,目前有多种新型药物处于实验室、临床前研究或临床研究阶段,如新型抗VEGF药物、新型给药方式或新型靶点药物等。眼科临床医生应该了解和关注各代抗VEGF药物治疗湿性AMD的优缺点及其新药的研究进展,更好地为湿性AMD患者治疗和服务。Wet age-related macular degeneration (AMD),which is the leading cause of visual impairment in elderly people,significantly affects quality of life of millions worldwide.Currently,anti-VEGF is the first-line therapy for wAMD,bringing encouraging results in improving the vision.However,not all of the patients will response to this therapy,moreover,anti-VEGF may be associated with several issues,such as multiple injections,systemic adverse effects,delay or lack of response.With a deep understanding of the mechanism of wAMD,there are rapid developments of new approaches to more effective therapy.Ophthalmologists should pay attention to the advantages and disadvantages of these anti-VEGF drugs as well as the current advances of anti-VEGF drugs in order to provide better treating strategies for wAMD patients better.

关 键 词：年龄相关性黄斑变性 血管内皮生长因子 单克隆抗体 融合蛋白 

分 类 号：R774.5[医药卫生—眼科]